Idiopathic CRMO and MEFV Gene Variant Alleles: Is There Any Relationship by صالح زاده, فرهاد et al.
Case Series
Idiopathic CRMO and MEFV Gene Variant Alleles: Is There
Any Relationship?
Farhad Salehzadeh ,1 Hassan Anari,2 and Sepehr Sarkhanloo 3
1Professor in Pediatric Rheumatology, Pediatric Department, Bouali Children’s Hospital,
Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran
2Assistant Professor in Radiology, Imam Khomeini Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran
3Pediatric Department, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran
Correspondence should be addressed to Sepehr Sarkhanloo; sepehr.sarkhanloo@gmail.com
Received 26 December 2018; Revised 11 February 2019; Accepted 6 March 2019; Published 27 March 2019
Academic Editor: Suleyman Serdar Koca
Copyright © 2019 Farhad Salehzadeh et al. *is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background and Objective. CRMO is an inﬂammatory disease of bone that occurs more often in children. *e clinical mani-
festations are intermittent fever, pain, and bone lesions, especially in long bones. Although there is an idiopathic type of disease, it
is usually associated with some autoimmune disorders. *is study evaluates MEFV gene mutations as background pathology of
idiopathic CRMO.Methods. Blood samples of patients, who diagnosed as childhood idiopathic CRMO by imaging and pathologic
study from June 2011 until September 2018, have been screened for the 12 common pathogenic variants ofMEFV gene mutations.
Result. Nine patients enrolled in this study, and eight of them were male. *e most common involvement locations were tibia and
femur, and the least ones were zygoma, calcaneus, and radius. *e mean duration of the involvement was 1.3 years. Six patients
had only 1 involved location, 2 patients showed two sites of involvement, and one patient had three aﬀected areas. *ere were two
positive MEFV gene mutations (22%), as E148Q/wt and K695R/wt both in the heterozygote form. *ere was no meaningful
relationship between MEFV gene mutations and the age of onset, gender, and location of involvement. Patients with positive
mutation had more involved sites and long duration of involvement signiﬁcantly. Conclusion. *ere is no signiﬁcant immu-
nopathogenic relationship between the common MEFV gene variant alleles and CRMO disease.
1. Introduction
CRMO (chronic recurrent multifocal osteomyelitis) also
known as chronic nonbacterial osteomyelitis is an in-
ﬂammatory disease of the bone that frequently occurs in
children [1, 2]. CRMO was ﬁrst deﬁned by Giedion et al. in
1972 [3]. In the past, CRMO was only known as a child-
speciﬁc disease but nowadays has been diagnosed in adults
as well [2]. *e condition is more likely to be between the
ages of 4 and 14 years (on average, ten years). *e frequency
of CRMO is 1 :1,000,000, and the ratio of female to male is 5
to 1 [3]. Clinical manifestations are intermittent fever, pain,
and bone lesions that can occur in all bones of the body,
especially long bones.
CRMO is known by chronic bone pain and often di-
agnosed following a lengthy process by bone biopsy andMRI.
*is condition is characterized by episodes of systemic
inﬂammation, including serological inﬂammation markers
(CRP, TNF-α, ESR, and IL-6) when autoantibodies or
pathogens are not present [4].
Despite recent scientiﬁc achievements, the exactmolecular
pathophysiology of CRMO is only incompletely understood.
Generally, familial (or monogenic) diseases including CRMO
as a descriptive symptom can be diﬀerentiated from the entity
of sporadic CRMO, by other disease features [5].
Diﬀerential diagnosis of CRMO is painful bone tumors
or lesions such as bacterial osteomyelitis, Ewing sarcoma,
leukemia, lymphoma, rhabdomyosarcoma, metastasis of
neuroblastoma, eosinophilic granuloma, or Langerhans cell
histiocytosis [6–9].
Imaging techniques are essentially important for di-
agnosing CRMO. Inﬂammatory bone lesions may be normal
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in early stages; but in later stages, in plain radiographs, it is
detected as radiolucent, sclerotic, or osteolytic lesions. In the
early stage of the disease, MRI is highly sensitive [5].
Treatment of patients with CNO/CRMO is based mainly
on expert opinion and relatively small case collections. It
usually involves nonsteroidal anti-inﬂammatory drugs
(NSAIDs), corticosteroids, disease-modifying antirheumatic
drugs (DMARDs, usually methotrexate or sulfasalazine),
anti-TNF agents, or bisphosphonates [5].
*is study was planned to evaluate the relationship
between CRMO and MEFV gene mutations as a possible
immunopathogenic background in idiopathic forms of
CRMO.
2. Methods
*is study included nine patients diagnosed with idio-
pathic CRMO at Bu Ali Hospital from 2011 to 2018. Data
obtained from their hospital ﬁle and after taking conﬁrmed
consent form, twelve common MEFV gene mutations
consisting of E148Q in exon 2, P369S in exon 3, F479L in
exon 5, M680I (G/C), M680I (G/A), I692del, M694V,
M694I, K695R, V726A, A744S, and R761H in exon 10,
were determined to investigate the prevalence of these
mutations.
*e samples were screened by an RDB assay (FMF
StripAssay, Vienna Lab, Vienna, Austria) according to the
manufacturer’s instructions.
In this study, after excluding primary diseases, we took a
thorough history of the patients and performed a complete
physical examination, plain radiography, MRI, whole body
bone scan with Tc-99mMDP, and biopsy (in some patients)
to diagnose CRMO.
All patients and their ﬁrst-degree families were screened
for the FMF signs and symptoms to exclude any background
of Mediterranean fever.
*e study was approved by the local ethical committee
with the number IR.ARUMS.REC.1396.261, and informed
consent was obtained from all the participants.
3. Results
Nine patients enrolled in this study, and eight of them were
male.*emean age of male patients was 6.9 years and female
was 16 years, and the average age of all patients was 9.7 years.
*emost frequent sites of involvement were tibia and femur,
and the least places were zygoma, calcaneus, and radius
bones (Table 1).
None of the patients had underlying diseases. Six pa-
tients (66.7%) had only one area of involvement. Two pa-
tients (22.2%) had two locales, and one patient (11.1%) had
three aﬀected regions. Two patients (male) showed positive
MEFV gene mutations.
*e ﬁrst patient had an E148Q/wt, and the second one
showed a K695R/wt as heterozygote mutation (Table 2).
*ere was no signiﬁcant relationship between the MEFV
mutations regarding the gender.
Radius and femur were dominant bones involved in
patients with positive mutations and patients without
mutations, and the most frequent involvement sites were
tibia and femur.
*ere was no signiﬁcant relationship between the in-
volved bones and MEFV gene mutations.
Regarding the duration of involvement, the average
duration in male was 1.3 years and in female was 1.0 and in
total was 1.2 years.
Patients with positive mutation had more involved sites
and long duration of involvement signiﬁcantly.
4. Discussion
CRMO is an uncommon type of osteomyelitis, presenting in
2–5% of all diagnoses. It is characterized by recurrent pe-
riods of focal, chronic, and multiple noninfectious, in-
ﬂammation of the bone along with exacerbations and
remissions.
Microorganisms including atypical mycobacteria, an-
aerobic streptococci, coagulase-negative staphylococci,
Propionibacterium acnes have been suggested as the cause,
but the etiology of CRMO is yet unknown [10].
It is worth bearing in mind that P. acnes is a common
organism in the skin and that any biopsy of the bone can also
contain some skin. Furthermore, P. acnes are commonly
detected as a contaminant in microbiological cultures, so its
role in CRMO is unclear [11].
Bone pain is usually the initial symptom, but the clinical
presentation of CRMO is variable [12].
CRMO can be associated with other inﬂammatory dis-
eases, such as SAPHO syndrome (synovitis, acne, pustulosis,
hyperostosis, and osteitis), psoriasis, IBD (Crohn’s disease
Table 1: Locations of involvement.
Percentage Patients Locations
11.1 1 Zygoma
22.2 2 Femur
11.1 1 Tibia
11.1 1 Radius
11.1 1 Calcaneus
22.2 2 Two locations
— 1 (i) Tibia and ﬁbula
— 1 (ii) Femur and ischiopubic joint
11.1 1 *ree locations
— 1 Humerus, mandible and femur
100 9 Total
Table 2: Summary of patient ﬁndings.
Sex Age/year Age onset ofsymptom Involved sites Mutations
1 F 17 5 1 —
2 M 4 2 1 —
3 M 13 4 3 —
4 M 10 9 1 —
5 M 11 6 1 —
6 M 10 4 1 K695R/wt
7 M 11 7 2 —
8 M 8 6 2 E148Q/wt
9 M 11 10 1 —
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and ulcerative colitis), peripheral arthritis, sacroiliitis, pal-
moplantar pustulosis and vasculitis, and granulomatosis with
polyangiitis. Majeed syndrome (characterized by CRMO and
congenital dyserythropoietic anemia) and Sweet syndrome
(acute febrile neutrophilic dermatosis) are other accompa-
nying disorders reported with CRMO [12–16].
Manson et al. [17] suggested diagnostic criteria which are
shown in Table 3. *e important feature of disease was the
plurality of single or multiple lesions [18]. *is study in-
cluded patients with a single lesion.
Autoinﬂammatory mechanisms are considered as a
probable cause of CRMO.
*e level of TNF- (tumor necrosis factor-) alpha was
reported to increase locally and systemically in patients with
active disease [2], suggesting a possible immune-mediated
etiology [11].
Instability between proinﬂammatory and anti-
inﬂammatory cytokines [19], and also increased IL-1β se-
cretion by peripheral mononuclear cells of patients with
CRMO during active disease [20], is known as an immune-
pathogenic process. IL-1 blocking agents and TNF-α in-
hibitors can be used in treatment because IL-1 and TNF-α
are essential in the pathogenesis of the disease [10].
*e distinctive feature of CRMO is aseptic osteitis.
However, a negative culture cannot deﬁnitively rule out an
infective etiology. It can be diﬃcult to diagnose when only
one site is involved. In these cases, a biopsy may be carried
out to exclude neoplastic and infectious diseases [21].
Biopsy and histological examination can support the
diagnosis but are not speciﬁc.
CRMO shares many histologic features with acute os-
teomyelitis such as granulocytic inﬁltration within aﬀected
lesions. *e inﬁltrates mainly consist of lymphocytes,
granulocytes, plasma cells, and histiocytes [22, 23].
*e prognosis generally is good, and symptom resolu-
tion is seen in most patients until adulthood [21, 24]. Some
studies have shown that up to 25% of patients have residual
disease that leads to skeletal deformity or painless limp
[24, 25].
Until recently, theMEFV gene had been considered to be
responsible only for FMF, but many reports show that the
MEFV gene is associated with additional clinical pre-
sentations within the family of the autoinﬂammatory dis-
eases such as recurrent monoarthritis, Behcet disease,
rheumatoid arthritis, and multiple sclerosis [26–28].
Recent reports of CRMO in the FMF patient [29] and
colchicine-responsive CRMO that introduced multifocal
osteomyelitis as a variant of familial Mediterranean fever
[30] elicited the possible relation between FMF,MEFV gene,
and CRMO.
In this study, the prevalence of the MEFV gene muta-
tions in CRMO patients was about 22%, which is not sig-
niﬁcantly diﬀerent from the mutation prevalence in the
normal population (25%) of this area (under published
data).
In this study, CRMO is signiﬁcantly higher in males,
while in other case series, the ratio of female to male has been
higher [10]. *ere was no signiﬁcant relationship between
age of onset of symptoms and MEFV gene mutations;
additionally regarding the sex, age, and area of involvement,
there was no any meaning full ﬁnding.
*ese common inﬂammatory MEFV gene mutations
seem to have no role in CRMO pathogenesis, and it is
unlikely that CRMO is to be a common clinical feature and
or the ﬁrst presentation of FMF patients.
5. Conclusion
Although CRMO is an AID, it seems that the MEFV gene
does not play any role in this inﬂammation, and it is unlikely
that CRMO is presenting feature of FMF disease.
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